American Association for Cancer Research
19406207capr140134-sup-130475_1_supp_2550684_n8cj41.pdf (44.81 kB)

Supplementary Table S1 from Biomarkers for Personalizing Omega-3 Fatty Acid Dosing

Download (44.81 kB)
journal contribution
posted on 2023-04-03, 19:28 authored by Yan Jiang, Zora Djuric, Ananda Sen, Jianwei Ren, Dmitry Kuklev, Ian Waters, Lili Zhao, Charis L. Uhlson, Yu H. Hong, Robert C. Murphy, Daniel P. Normolle, William L. Smith, Dean E. Brenner

Table S1 shows the composition of diets fed to F344 rats.



Prostaglandin E2 (PGE2) has been linked to a higher risk of colorectal cancer. PGE2 in colon tissue can be reduced by increasing dietary eicosapentaenoic acid (EPA). The dose-dependent relationships between dietary EPA, serum EPA:arachidonate (AA) ratio, urinary PGE2 metabolites, and colonic eicosanoids were evaluated to develop biomarkers for prediction of colonic PGE2. Male rats were fed diets containing EPA:ω6 fatty acid ratios of 0, 0.1, 0.2, 0.4, or 0.6 for 5 weeks. Increasing the dietary EPA:ω6 fatty acid ratio increased EPA:AA ratios in serum and in the proximal, transverse, and distal colon (P < 0.001). The urinary PGE2 metabolite was reduced (P = 0.006). EPA-rich diets reduced colonic tissue PGE2 concentrations by 58% to 66% and increased PGE3 by 19- to 28-fold. Other AA–derived eicosanoids were reduced by 35% to 83%. The changes were not linear, with the largest changes in eicosanoids observed with the lower doses. A mathematical model predicts colonic tissue eicosanoids from the EPA:AA ratio in serum and the EPA dose. Every 10% increase in serum EPA:AA was associated with a 2% decrease in the (geometric) mean of PGE2 in the distal colon. These mathematical relationships can now be applied to individualized EPA dosing in clinical trials. Cancer Prev Res; 7(10); 1011–22. ©2014 AACR.